囊性纤维化的治疗满意度：患者早期使用妥布霉素吸入粉的体验
Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder.
作者信息
Greenberg Jonathan, Palmer Jacqueline B, Chan Wing W, Correia Catherine E, Whalley Diane, Shannon Paul, Sawicki Gregory S
机构信息
Division of Respiratory Diseases, Boston Children's Hospital, Boston, MA.
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
出版信息
Patient Prefer Adherence. 2016 Oct 26;10:2163-2169. doi: 10.2147/PPA.S102234. eCollection 2016.
BACKGROUND
This study assessed treatment satisfaction of cystic fibrosis (CF) patients in a routine clinical setting for tobramycin inhalation powder (TIP), the first dry powder-inhaled antibiotic for infection.
METHODS
CF patients aged 6 years or older treated with at least one cycle of TIP completed a web survey on experience with TIP, including the Treatment Satisfaction Questionnaire for Medication (TSQM). Regression analysis determined the factors associated with TSQM global satisfaction.
RESULTS
Eighty patients (mean age ± standard deviation: 24.4±9.4 years; 57.5% female; mean forced expiratory volume in 1 second ± standard deviation: 67.1%±27.3% predicted) completed the survey. The majority expressed satisfaction with TIP's administration time (100%), time to clean (97.1%), portability (97.1%), and ease of use (94.3%). Effectiveness was significantly associated with TSQM global satisfaction (regression -squared: 0.54).
CONCLUSION
Patient preferences for TIP were based on administration time and ease of use. Global satisfaction was related to greater patient-perceived effectiveness.
背景
本研究在常规临床环境中评估了囊性纤维化（CF）患者对妥布霉素吸入粉（TIP）的治疗满意度，TIP是首款用于感染的干粉吸入抗生素。
方法
接受至少一个周期TIP治疗的6岁及以上CF患者完成了一项关于TIP使用体验的网络调查，包括药物治疗满意度问卷（TSQM）。回归分析确定了与TSQM总体满意度相关的因素。
结果
80名患者（平均年龄±标准差：24.4±9.4岁；57.5%为女性；一秒用力呼气量平均±标准差：占预计值的67.1%±27.3%）完成了调查。大多数患者对TIP的给药时间（100%）、清洁时间（97.1%）、便携性（97.1%）和易用性（94.3%）表示满意。有效性与TSQM总体满意度显著相关（回归平方：0.54）。
结论
患者对TIP的偏好基于给药时间和易用性。总体满意度与患者感知到的更高有效性相关。
Zotero 插件